

The AID/APOBEC family of nucleic acid mutators

Silvestro G Conticello

Address: Core Research Laboratory - Istituto Toscano Tumori, Florence, Via Cosimo il Vecchio 2, 50139 Firenze, Italy.
Email: silvo.conticello@ittumori.it

Published: 17 June 2008

Genome Biology 2008, **9**:229 (doi:10.1186/gb-2008-9-6-229)

The electronic version of this article is the complete one and can be found online at <http://genomebiology.com/2008/9/6/229>

© 2008 BioMed Central Ltd

Summary

The AID/APOBECs, a group of cytidine deaminases, represent a somewhat unusual protein family that can insert mutations in DNA and RNA as a result of their ability to deaminate cytidine to uridine. The ancestral AID/APOBECs originated from a branch of the zinc-dependent deaminase superfamily at the beginning of the vertebrate radiation. Other members of the family have arisen in mammals and present a history of complex gene duplications and positive selection. All AID/APOBECs have a characteristic zinc-coordination motif, which forms the core of the catalytic site. The crystal structure of human APOBEC2 shows remarkable similarities to that of the bacterial tRNA-editing enzyme TadA, which suggests a conserved mechanism by which polynucleotides are recognized and deaminated. The AID/APOBECs seem to have diverse roles. AID and the APOBEC3s are DNA mutators, acting in antigen-driven antibody diversification processes and in an innate defense system against retroviruses, respectively. APOBEC1 edits the mRNA for apolipoprotein B, a protein involved in lipid transport. A detailed understanding of the biological roles of the family is still some way off, however, and the functions of some members of the family are completely unknown. Given their ability to mutate DNA, a role for the AID/APOBECs in the onset of cancer has been proposed.

Gene organization and evolutionary history

The AID/APOBEC proteins are found in vertebrates and share the ability to insert mutations in DNA and RNA by deaminating cytidine to uridine. The first family member to be identified and characterized was the apolipoprotein B editing complex 1 (APOBEC1), a protein involved in the editing of the apolipoprotein B (ApoB) pre-mRNA [1,2]. Further members were identified as DNA mutators. Activation-induced deaminase (AID) was revealed to be essential for the antigen-driven diversification of already rearranged immunoglobulin genes in the vertebrate adaptive immune system [3], and the APOBEC3s were shown to be involved in the restriction of retrovirus propagation in primates [4,5]. The other members of the family, APOBEC2 and APOBEC4, have not yet been characterized. Table 1 lists the human AID/APOBEC paralogs; family members from other species are listed in Additional data files 1 and 2.

All the AID/APOBECs share the structural and catalytic backbone of the zinc-dependent deaminases, a large gene

superfamily encoding enzymes involved in the metabolism of purines and pyrimidines (Figure 1). Of these deaminases, the tRNA adenosine deaminases (Tad/ADAT2) edit adenosine to inosine at the anticodon of various tRNAs in both eukaryotes and prokaryotes [6] and are thought to be the group from which the AID/APOBEC family originated (Figure 1). Indeed, as well as having functional and structural similarities to the AID/APOBECs [7,8], ADAT2 from trypanosomes seems to be able to deaminate cytidine in DNA [9].

The rise of the AID/APOBEC gene family appears to have been concurrent with the appearance of the vertebrate lineage and the evolution of adaptive immunity and AID is thought to be one of the ancestral family members (Figure 2). AID homologs able to trigger somatic hypermutation and class-switch recombination in B cells have been described in bony fish [10,11], while *bona fide* AID homologs have been identified both in cartilaginous fish [10], which have immunoglobulin genes, and in the sea

Table 1**Human AID/APOBEC paralogs**

Name	Genomic location	Exons	Deaminase domains	Expression	Cellular localization	Editing activity	Target	References
AID	12p13	5	1	Activated B cells, testis	Mainly cytoplasmic, acts in the nucleus	DNA	Immunoglobulin gene	[3,31]
APOBEC1	12p13.1	5	1	Small intestine	Cytoplasmic/nuclear, acts in the nucleus	RNA, DNA	Apolipoprotein B mRNA	[1,2]
APOBEC2	6p21	3	1	Skeletal muscle, heart	Cytoplasmic/nuclear	Unknown	Unknown	[15,16]
APOBEC3A	22q13.1	5	1	Keratinocytes, blood	Predominantly nuclear	DNA	Adeno-associated virus, retrotransposons	[4,104]
APOBEC3B	22q13.1	8	2	Intestine, uterus, mammary gland, keratinocytes, other	Cytoplasmic/nuclear	DNA	Retroviruses, retrotransposons, HBV	[4,104]
APOBEC3C	22q13.1	4	1	Many tissues	Cytoplasmic/nuclear	DNA	Retroviruses, retrotransposons, HBV	[4]
APOBEC3DE	22q13.1	7	2	Thyroid, spleen, blood	Unknown	DNA	Retroviruses	[4,10,107]
APOBEC3F	22q13.1	8	2	Many tissues	Cytoplasmic	DNA	Retroviruses, retrotransposons, HBV	[4]
APOBEC3G	22q13.1	8	2	Many tissues, T cells	Cytoplasmic	DNA	Retroviruses, retrotransposons, HBV	[4,5]
APOBEC3H	22q13.1	5	1	Blood, thymus, thyroid, placenta	Unknown	DNA	Retroviruses	[10,107]
LOC196469*	12q23	1	2	Pseudogene	-	-	-	[10,107]
APOBEC4	1q25.3	2	1	Testis	Unknown	Unknown	Unknown	[14]

*This pseudogene originated from a recent retrotranspositional event. HBV, hepatitis B virus.


lamprey, a jawless vertebrate [12], which does not. The presence of AID in the lamprey is remarkable, as its system of 'adaptive immunity' is based not on immunoglobulins but on variable lymphocyte receptors (VLRs), a large family of proteins containing leucine-rich repeats, which undergo at least one round of diversification [12,13]. It will be interesting to know whether the sea lamprey AID homolog is involved in this process.

The gene structure for most AID/APOBECs genes includes five exons and is reminiscent of that of the DCDT (dCMP deaminases)/ADAT2 genes, in which the catalytic site is encoded in the third exon. In contrast, the other ancestral AID/APOBEC genes, namely *APOBEC4* [14] and *APOBEC2* [15,16] (found in all jawed vertebrates, see Figure 2), have two and three exons respectively, with the coding sequence being mostly confined to the second exon. The few amino acids encoded by the first exon of *APOBEC2* have no similarity to any known sequence. These observations provide clues to the overall evolution of the gene family: the absence of introns in the deaminase-like region of *APOBEC4* and *APOBEC2* suggests that these genes might be the result of early retrotranspositional events. Given the position of the sea lamprey deaminase genes (*AID-CDA1* and *CDA2*) in the

phylogenetic tree (see Figure 2), the *APOBEC4* clade seems to have evolved independently from that of AID, while the clustering of *APOBEC2* raises the possibility that AID provided its evolutionary scaffold. The phylogenetic relationships and gene structure of the later-evolved members of the family (*APOBEC1* and *APOBEC3*) indicate that they have originated from sequential duplications of the AID locus.

The *APOBEC1* locus derives from an inverted duplication of the AID locus on the same chromosome, located 40 kb away in most mammals. *APOBEC1* homologs with the same genomic orientation are found in marsupials. In primates, owing to an inversion, the *APOBEC1* locus is located approximately 1 Mb away from the AID locus [10]. The main difference between *APOBEC1* and the other AID/APOBEC genes is an extended coding sequence at its 3' end, whose significance has yet to be understood.

The *APOBEC3* locus [4] originated after the divergence of the marsupial and placental lineages and is located in the region syntenic with human chromosome 22q13. A duplication event in the original 'placental' locus formed the two ancestral *APOBEC3* genes, from which all other *APOBEC3*s have evolved through a complex history of gene

**Figure 1**

Schematic representation of the evolutionary relationships between the AID/APOBECs and the rest of the zinc-dependent deaminases. The only other zinc-dependent deaminase families widely expressed in metazoans and from which the AID/APOBECs (shaded in red) could have originated are the cytidine deaminases (CDA), the dCMP deaminases (DCDT) or the tRNA adenosine deaminases (Tad/ADAT2) (all shown in orange). CDAs and DCDTs act on free pyrimidines in the salvage pathway, the Tad/ADAT2s edit adenosine 34 at the anticodon of various tRNAs to inosine and are essential in bacteria, yeast and metazoans [6]. AID/APOBECs are unlikely to have originated from CDAs because of the differences in gene organization and catalytic domain [7,10]; DCDTs, despite the similar secondary structure, differ substantially from the AID/APOBECs in their substrate (free nucleotides), dependency on Mg and dCTP, and aggregation into homohexamers [108]. Phylogenetic data [10], species representation, and structural/functional features favor the tRNA-editing enzymes as the origin of the AID/APOBECs [7,8], a model supported by the observation that ADAT2 from trypanosomes can deaminate DNA [9]. The tRNA^{Ala} adenosine 37 deaminases type I (ADAT1) and the mRNA adenosine deaminases 1, 2, and 3 (ADARs) (shaded in green) are thought to have originated from the Tad/ADAT2 family independently of the AID/APOBECs. CoDA, cytosine deaminases; RibD, riboflavin deaminases; GuanineD, guanine deaminases.

duplications and fusions [10,17]. In some species, such as rodents, pigs and cattle, the two original genes have merged to form a single gene with a double zinc-coordinating domain, whereas in other species - primates, horses, bats, and felines - one of the two genes has been repeatedly duplicated to form an array of *APOBEC3* genes. In primates in particular, the locus has rapidly expanded to seven genes. This rapid evolution of the *APOBEC3* locus is thought to be

the result of selective pressure on the APOBEC3s from their targets (retroviruses and retrotransposons) [18,19].

Characteristic structural features

Until very recently a crystal structure for a functionally characterized AID/APOBEC was not available and many of the structural features of this protein family have been ascertained by comparing their primary and secondary structure with the crystal structures of the functionally uncharacterized APOBEC2 [20] and of other zinc-dependent deaminases, especially TadA from the Tad/ADAT2 family [21]. The three-dimensional structure of the carboxy-terminal domain of APOBEC3G has now been published [22]. This model shows the closeness between the APOBEC3G structure and those already known.

Like all zinc-dependent deaminases, the main structural feature of the AID/APOBECs is the domain responsible for their catalytic activity. In the amino-acid sequence, the signature for this domain is a H[AV]E-x_[24-36]-PCxxC motif (where x is any amino acid) (Figure 3). The histidine (H) and the two cysteines (C) coordinate a zinc atom and form the catalytic core of the deaminase (Figure 4). The cytidine is bound in this pocket and is deaminated through nucleophilic attack on the ammonium group on its carbon 4 by an activated water molecule (coordinated by the zinc atom) and the nearby glutamate, which acts as a proton donor.

The overall structure of the AID/APOBECs resembles that of other zinc-dependent deaminases. A series of five β strands forms the backbone of the molecule and α helices 2 and 3 hold the histidine and the cysteines in place and thus shape the catalytic pocket (Figure 4). Structural similarities with the Tad/ADAT2s in particular provide clues to the ability of the AID/APOBECs to deaminate cytidine. A comparison with the crystal structure of the bacterial TadA protein bound to its substrate [21] reveals the presence of a conserved loop (labeled in orange in Figure 4) that may play a role in substrate recognition [7,8]. A serine-tryptophan-serine (SWS) motif (corresponding to SSS in APOBEC2) located before the PCxxC motif is necessary for catalytic activity [23] (labeled in pink in Figure 4). This structural arrangement forms a trough where the DNA strand could be positioned and recognized. Recognition of the substrate through these loops might explain the observation that different AID/APOBECs display sequence-context preferences in regard to the nucleotides immediately upstream of the cytidine to be deaminated (see for example [24-26]).

Dimerization/oligomerization of the AID/APOBECs has been reported, often occurring in an RNA-dependent manner ([20,27-29] and references therein), but, in the case of AID and APOBEC3G, the quaternary structure does not seem to be necessary for the enzymatic activity (see for example [30]).





Figure 2
 Phylogenetic relationships within the AID/APOBEC gene family. The neighbor-joining tree shown here is generated from a protein alignment of the exon encoding the zinc-coordinating motif (the alignment is provided as Additional data file 1). The position of the agnathan (sea lamprey) AID (indicated by the arrow), separated from the clade comprising all the other AID/APOBECs, could suggest that all family members have originated from the ancestral AID. The different clusters in the AID/APOBEC family are identified, with the APOBEC3 cluster further divided into Z1a, Z1b, and Z2 clades (for the nomenclature of the APOBEC3 subgroups see [10]). Each domain of the double-domained APOBEC3s is included individually, with the amino-terminal and carboxy-terminal domains labeled [N] and [C], respectively. While APOBEC1 has been described only in mammals, the APOBEC2 group is found in all jawed vertebrates, including the primitive ghost shark. The duplication of the *APOBEC2* locus after an ancient genome duplication in bony fish has been maintained, resulting in two coevolving *APOBEC2* genes. The organisms in which each group is found are indicated below the clade label. Clades are collapsed for clarity, and only nodes with a bootstrap value greater than 50 are shown. The sequences used are either described in [10,12] or obtained from the Ensembl Genome Browser [109]. The sequences for the ghost shark were obtained using the AID/APOBECs as queries in BLAST searches on the *Callorhynchus milii* genome shotgun contigs (GenBank accession numbers: AID, AAVX01329030; APOBEC2, AAVX01039499; APOBEC4, AAVX01642881).

**Figure 3**

Logo alignment of the exon encoding the zinc-coordinating motif in the AID, APOBEC1, APOBEC3, and APOBEC2 clusters. The height of the letter represents the conservation of that given residue. The zinc-coordinating H[AV]E-x(24-36)-PCxxC motif is labeled. The secondary structure, predicted from the APOBEC2 structure, is shown below the alignment. The α helices are shown as cylinders and the β -strands as arrows. α Helices 2 and 3, providing the scaffold for the catalytic core, are labeled in blue. The conserved loops that might have a role in substrate recognition are color-coded (pink and orange) and indicated by arrows. The Logo alignment was generated using WebLogo [110] on a subset of the alignment provided as Additional data file 1 in which APOBEC4 and outgroup sequences were excluded.

**Figure 4**

Three-dimensional structure of APOBEC2 [20]. α Helices 2 and 3, which hold the histidine and the cysteines forming the catalytic pocket, are indicated in blue. The zinc atom is indicated as a yellow sphere, the residues coordinating the zinc atom are colored in red, and the glutamate acting as proton donor in purple (beneath the zinc atom). The β strands providing the molecule's scaffold are indicated in bright green. The loops that might play a role in substrate recognition are indicated: the loop conserved in Tada [21] is in orange and the SSS loop is in pink. PDB: 2NYT.

Localization and function

The known functions of the AID/APOBECs revolve around their ability to get, more or less specifically, to their substrate and deaminate it. This means that, given the diverse roles that the AID/APOBECs perform, their cellular localization varies. Nonetheless, most AID/APOBECs are initially localized to the cytoplasm, a safe place considering their ability to mutate DNA.

AID

AID was first discovered in 1999 in a subtractive hybridization screen comparing switch-induced and uninduced murine B lymphoma cells [3] and it is selectively expressed in activated B cells in germinal centers. Subsequent genetic experiments have revealed that AID is central to antigen-driven antibody diversification by class-switch recombination, somatic hypermutation, or gene conversion [31-33]. Genetic AID deficiency leads to Type 2 Hyper-IgM Syndrome [34], an immunodeficiency in which the inability to carry out class-switch recombination leads to the absence of antibodies other than those of the IgM class.

AID was initially thought to be an RNA-editing enzyme, but the discovery that it could mutate *Escherichia coli* DNA provided insight into its mechanism of action [35]. The ability of AID to deaminate C to U in DNA is in keeping with the observation that there are two mutational phases during the somatic hypermutation process. Further confirmation of its role as a DNA mutator came from evidence that uracil DNA glycosylase (UNG), the enzyme responsible for the removal of uracil in DNA, acts downstream of AID [36,37]. In humans, mutations in the UNG gene cause Type 5 Hyper-IgM Syndrome [37].

Further studies revealed that AID targets single-stranded DNA (see for example [38]) with a preference for cytidines within a sequence motif WRC (W is A or T; R is A or G) [24,39]. These observations are consistent with the presence of mutational hotspots at the immunoglobulin locus and the need for transcription (making single-stranded DNA available) for the antibody diversification processes to occur ([40] and references therein). Following deamination to uracil, recruitment of the general DNA repair machinery results in both somatic mutation and the initiation of class-switch recombination ([41] and references therein).

Whereas the function of AID is exerted in the nucleus, AID is predominantly cytoplasmic owing to the presence of a nuclear export signal (NES) at the extreme carboxyl terminus [42-44]. Accumulation of AID in the nucleus of murine B cells after ablation of the NES does not increase somatic hypermutation at the immunoglobulin locus, but causes an increase in non-physiologic hypermutation elsewhere in the genome [43]. Intriguingly, the same region is deemed necessary for the successful initiation of class-switch recombination, but it is not clear whether there is a causal relation between nuclear export and this process [45]. The presence of a weak nuclear localization signal (NLS) in the AID amino-terminal region has also been reported [42,44,45].

APOBEC1

APOBEC1 is expressed in the human small intestine and in the liver in rodents. It is responsible for *ApoB* pre-mRNA editing [1,2]: deamination of cytidine 6666 changes a glutamine codon into a stop codon, thus generating a shorter form of ApoB (ApoB48). ApoB48 is the main component in the hydrophilic shell of the chylomicrons, the very low-density lipoproteins that transport triglycerides from the intestine to the tissues.

Like AID, APOBEC1 acts in the nucleus [46] and shuttles between cytoplasm and nucleus by virtue of an amino-terminal NLS and a carboxy-terminal NES [47,48]. APOBEC complementation factor (ACF) is known to target APOBEC1 and leads to suppression of the edited *ApoB* mRNA non-sense-mediated decay (see for example [49]). Intriguingly, while the only phenotype in *APOBEC1*-deficient mice is the lack of *ApoB* mRNA editing (see for example [50]), ACF deficiency is lethal [51]. This, together with the conservation of the *ACF* gene throughout metazoans, could mean that AID/APOBECs were co-opted for *ApoB* mRNA editing only at a later stage in evolution, after the *AID* gene had been duplicated and the newly formed *APOBEC1* was free to evolve.

While AID and the APOBEC3s have a loose sequence context preference for cytidine deamination, APOBEC1 is part of a complex that strictly recognizes a sequence 3' to the cytidine to be deaminated (the mooring sequence). After binding of the editing complex to an AU-rich motif, overlapping with the mooring sequence, APOBEC1 edits the C6666. The

efficiency of editing is also mediated by a number of other *cis*-acting elements ([52] and references therein). While there is no doubt on the physiological role for APOBEC1, its overexpression causes deamination of various RNAs in a promiscuous manner (see for example [53,54]). Intriguingly, APOBEC1 can also deaminate cytidine in DNA [23,55], which might suggest additional functions for it, maybe more related to those of the other AID/APOBECs.

The APOBEC3s

The APOBEC3s were first identified as paralogs of APOBEC1 by Jarmuz *et al.* [4], but attained the limelight when human APOBEC3G was identified as the factor involved in HIV restriction [5]. HIV mutants lacking the viral infectivity factor (Vif) are non-infective in certain cell lines (so-called nonpermissive cell lines) but will propagate in others (permissive cell lines). *APOBEC3G* mRNA was isolated through a cDNA subtraction screen between CEM (nonpermissive) and CEM-SS (permissive) cells; its overexpression in CEM-SS cells reverses the permissive phenotype to nonpermissive [5].

APOBEC3G is packaged into the HIV virion and exerts its action on the nascent first DNA strand produced by reverse transcription in the target cell [56-60]. As a consequence, the viral genome is prevented from integrating into the cell's genome and those rare retrotranscripts that do succeed in integrating are heavily mutated and nonfunctional. APOBEC3G produces characteristic G to A mutations on the viral plus-strand cDNA, and in experimental conditions the mutation load on the viral genome can be as high as 3%.

In the presence of Vif, however, APOBEC3G is not able to prevent HIV propagation as it is ubiquitinated and targeted for proteasomal degradation - via a Cul5-SCF complex - when it interacts with Vif through its amino-terminal domain (see for example [61,62]). It is interesting to note that the interaction with Vif has shaped the evolution of APOBEC3G: a single amino-acid change among primate APOBEC3Gs confers resistance to other primate lentiviral Vif proteins (see for example [63]).

Like APOBEC3G, all the primate APOBEC3 paralogs are able to restrict retroviruses with varying efficiency (Table 1). APOBEC3F, which has similar activity and expression pattern to APOBEC3G, preferentially deaminates cytidines, but in a different sequence context (see for example [25,26,64]). Interestingly, an analysis of HIV sequences hypermutated *in vivo* reveals a mutational bias toward the sequence preferences of APOBEC3G and F [24,65].

Most cellular APOBEC3G is kept inactive in high molecular weight ribonucleoprotein complexes [28,29,66]. Its packaging into virions is mediated by both viral and cellular RNAs [67-72], although the HIV Gag protein increases packaging efficiency [70,72,73]. For enzymatic activity to

be displayed, the balance between high molecular weight and low molecular weight APOBEC3G complexes must be reversed [28] and, even after being packaged into virions, APOBEC3G must be freed by the action of RNase H during retrotranscription [66]. Indeed, the avidity of APOBEC3G for RNA and its localization in mRNA-processing bodies in the cytoplasm (see for example [74]) could serve as both regulatory and targeting mechanisms, and these properties might shed light on novel functions for APOBEC3s, such as involvement in microRNA regulation [75].

Given the similarities in the replication mechanisms, the APOBEC3s are able to restrict both retrotransposons and viruses with a reverse transcription step during their replication cycle ([7,76] and references therein).

Uncharacterized APOBECs

APOBEC2 [15,16], the only AID/APOBEC member until very recently for which a crystal structure was available [20], is expressed specifically in skeletal muscle and heart. It has proved the most elusive AID/APOBEC to characterize functionally, mainly because it has none of the enzymatic activities typical of its paralogs [15,16,23,77]. APOBEC2 does not seem necessary for mouse development [77], but it is noteworthy that its appearance during metazoan evolution coincides with the evolution of slow/fast striated muscle and cardiac muscle [78,79]. Moreover, as with AID, the purifying selection driving the evolution of APOBEC2 at both the inter-species and intra-species level (bony fish have two copies of the gene) [7,18] suggests an evolutionary history constrained by function.

Very little is known about APOBEC4, the most recently identified AID/APOBEC [14]. Its low sequence similarity to the other AID/APOBECs casts doubt on its ability to deaminate cytidine [7], but its ancestry might reveal novel links to the tRNA-editing enzymes and provide clues to the origin of the AID/APOBECs.

Frontiers

Despite the rapid progress in research on the AID/APOBECs, many questions remain. Apart from AID, the ancestral AID/APOBECs have not been functionally characterized. Moreover, while the enzymatic mechanisms of the characterized AID/APOBECs are now well known, the upstream and downstream events that mediate their action, and their involvement in other biological pathways are not yet known.

The physiological targets of APOBEC3s and retroviral inactivation

There have been a number of reports suggesting that the antiretroviral activity of the APOBEC3s could be dissociated from their ability to deaminate DNA ([80] and references therein), but with a finer calibration of the experimental system, the only significant antiviral activity is likely to be

due to the deaminase activity [81-83]. This highlights the difficulty in assaying the relevance of potential targets of APOBEC3s: the typical experimental system is based on transient overexpression of the enzyme together with the relevant retrovirus, followed by assessment of the infectivity of the viral particles in target cells. While this system can be used to test for novel APOBEC3 targets, it cannot be easily tuned to simulate the endogenous levels of the APOBEC3s. Thus the only known physiological target for endogenous APOBEC3s is HIV, and the G to A mutational bias observed in mobile elements [84,85] is the only indication of an involvement of the APOBEC3s in inhibiting their transposition *in vivo*. New tools to study the targets of the APOBEC3s in a more physiological manner are needed.

As discussed above, retroviral inactivation by APOBEC3s is due to the resulting inability of the retroviruses (or other mobile elements) to be integrated into the target-cell genome [26,57]. While a role for DNA glycosylases in trashing the APOBEC3-modified viral genome was initially hypothesized, this is not the case [82,83,86,87], and other hypotheses need to be tested (for example, inefficient retrotranscription [88]). But it will be difficult to prove this without being able to assay APOBEC3s at their endogenous levels.

Targeting AID to the immunoglobulin locus

Little is known of the mechanisms that lead AID to act specifically on the rearranged variable regions of immunoglobulin genes in antigen-activated B cells. Although *cis*-acting elements that might help determine specificity have been identified (for a review see [40]), a *trans*-acting machinery is likely to play a major role in this targeting. Few proteins that interact with AID have been identified so far: MDM2, a regulatory protein shuttling between cytoplasm and nucleus [89] and replication protein A (RPA), a ubiquitous protein that binds single-stranded regions of DNA in DNA replication and repair [90]. While this property of RPA makes its association with AID intriguing, its lack of specificity cannot explain the physiological targeting to the immunoglobulin locus. Moreover, murine AID needs to be phosphorylated in order to trigger antibody diversification and AID is associated with protein kinase A (PKA) [91-93]. Yet, AID phosphorylation is not specific to B cells [94], it is not required for the fish homolog to act [95], and phosphorylation-defective AID mutants show delayed activity in somatic hypermutation and its substantial decrease [92]. These findings suggest that phosphorylation might be more related to AID modulation than to its targeting.

AID/APOBECs and cancer

While the AID/APOBECs are powerful tools for improving the immune response, it is clear that their unique activity - inserting mutations in nucleic acids - represents a double-edged sword in cellular metabolism. Transgenic mice overexpressing APOBEC1 and AID develop tumors [96,97],

and the mutational context of C to T changes in genes commonly mutated in cancer is consistent with the action of these deaminases [24]. In addition, the AID/APOBECs are widely expressed in cancer tissues and cell lines [4,23,98].

It was known even before the identification of AID that a number of genes were mutated as a byproduct of antibody diversification processes and that mutations and aberrations in some of these genes were specific to cancers of the B-cell lineage. AID has subsequently been proved to trigger *c-myc/Igh* translocations (a common trait in Burkitt's lymphoma) in Balb/c mice [99-101]. Furthermore, expression of AID is needed in order to develop germinal-center-derived lymphomas in cancer-prone mice [102], and its aberrant expression might also have a role in the development of cancer (see for example [103]).

While there is no experimental evidence for the involvement of the APOBEC3s in cancer, they were first identified in keratinocytes treated with PMA, a phorbol ester known to be a skin tumor promoter [104]. Moreover, the induction of these mutators by viral infection [105] or antiviral pathways [106] could be the key to their role in cancer.

In the end, given that an association between the AID/APOBECs and the onset of cancer has been established, it needs to be ascertained whether this is due to stochastic events - unavoidable side effects of a mutational machinery - or if there are specific conditions that might induce aberrant function. This will only be achieved by an in-depth knowledge of the physiological roles of the AID/APOBECs.

Additional data files

Additional data is available online with this article. Additional data file 1 contains the alignment of the protein sequences used to calculate the phylogenetic tree shown in Figure 2. Additional data file 2 is a detailed version of the phylogenetic tree shown in Figure 2.

Acknowledgements

Helpful discussions with C Rada, MA Langlois, M Wang and JM Di Noia have influenced the writing of this review. This work was supported by an institutional grant from the Istituto Toscano Tumori.

References

- Navaratnam N, Morrison JR, Bhattacharya S, Patel D, Funahashi T, Giannoni F, Teng BB, Davidson NO, Scott J: **The p27 catalytic subunit of the apolipoprotein B mRNA editing enzyme is a cytidine deaminase.** *J Biol Chem* 1993, **268**:20709-20712.
- Teng B, Burant CF, Davidson NO: **Molecular cloning of an apolipoprotein B messenger RNA editing protein.** *Science* 1993, **260**:1816-1819.
- Muramatsu M, Sankaranand VS, Anant S, Sugai M, Kinoshita K, Davidson NO, Honjo T: **Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells.** *J Biol Chem* 1999, **274**:18470-18476.
- Jarmuz A, Chester A, Bayliss J, Gisbourne J, Dunham I, Scott J, Navaratnam N: **An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22.** *Genomics* 2002, **79**:285-296.
- Sheehy AM, Gaddis NC, Choi JD, Malim MH: **Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein.** *Nature* 2002, **418**:646-650.
- Gerber AP, Keller W: **An adenosine deaminase that generates inosine at the wobble position of tRNAs.** *Science* 1999, **286**:1146-1149.
- Conticello SG, Langlois MA, Yang Z, Neuberger MS: **DNA deamination in immunity: AID in the context of its APOBEC relatives.** *Adv Immunol* 2007, **94**:37-73.
- Conticello SG, Langlois MA, Neuberger MS: **Insights into DNA deaminases.** *Nat Struct Mol Biol* 2007, **14**:7-9.
- Rubio MA, Pastar I, Gaston KW, Ragone FL, Janzen CJ, Cross GA, Papavasiliou FN, Alfonzo JD: **An adenosine-to-inosine tRNA-editing enzyme that can perform C-to-U deamination of DNA.** *Proc Natl Acad Sci USA* 2007, **104**:7821-7826.
- Conticello SG, Thomas CJ, Petersen-Mahrt SK, Neuberger MS: **Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases.** *Mol Biol Evol* 2005, **22**:367-377.
- Saunders HL, Magor BG: **Cloning and expression of the AID gene in the channel catfish.** *Dev Comp Immunol* 2004, **28**:657-663.
- Rogozin IB, Iyer LM, Liang L, Glazko GV, Liston VG, Pavlov YI, Aravind L, Pancer Z: **Evolution and diversification of lamprey antigen receptors: evidence for involvement of an AID-APOBEC family cytosine deaminase.** *Nat Immunol* 2007, **8**:647-656.
- Nagawa F, Kishishita N, Shimizu K, Hirose S, Miyoshi M, Nezu J, Nishimura T, Nishizumi H, Takahashi Y, Hashimoto S, Takeuchi M, Miyajima A, Takemori T, Otsuka AJ, Sakano H: **Antigen-receptor genes of the agnathan lamprey are assembled by a process involving copy choice.** *Nat Immunol* 2007, **8**:206-213.
- Rogozin IB, Basu MK, Jordan IK, Pavlov YI, Koonin EV: **APOBEC4, a new member of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases predicted by computational analysis.** *Cell Cycle* 2005, **4**:1281-1285.
- Liao W, Hong SH, Chan BH, Rudolph FB, Clark SC, Chan L: **APOBEC-2, a cardiac- and skeletal muscle-specific member of the cytidine deaminase supergene family.** *Biochem Biophys Res Commun* 1999, **260**:398-404.
- Anant S, Henderson JO, Mukhopadhyay D, Navaratnam N, Kennedy S, Min J, Davidson NO: **Novel role for RNA-binding protein CUGBP2 in mammalian RNA editing. CUGBP2 modulates C to U editing of apolipoprotein B mRNA by interacting with apobec-1 and ACF, the apobec-1 complementation factor.** *J Biol Chem* 2001, **276**:47338-47351.
- Muenk C, Beck T, Zielonka J, Hotz-Wagenblatt A, Chareza S, Battenberg M, Thielebein J, Cichutek K, Bravo IG, O'Brien S, Loechelt M, Yuhki N: **Functions, structure, and read-through alternative splicing of feline APOBEC3 genes.** *Genome Biol* 2008, **9**:R48.
- Sawyer SL, Emerman M, Malik HS: **Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G.** *PLoS Biol* 2004, **2**:E275.
- Zhang J, Webb DM: **Rapid evolution of primate antiviral enzyme APOBEC3G.** *Hum Mol Genet* 2004, **13**:1785-1791.
- Prochnow C, Bransteitter R, Klein MG, Goodman MF, Chen XS: **The APOBEC-2 crystal structure and functional implications for the deaminase AID.** *Nature* 2007, **445**:447-451.
- Losey HC, Ruthenburg AJ, Verdine GL: **Crystal structure of *Staphylococcus aureus* tRNA adenosine deaminase TadA in complex with RNA.** *Nat Struct Mol Biol* 2006, **13**:153-159.
- Chen KM, Harjes E, Gross PJ, Fahmy A, Lu Y, Shindo K, Harris RS, Matsuo H: **Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G.** *Nature* 2008, **452**:116-119.
- Harris RS, Petersen-Mahrt SK, Neuberger MS: **RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators.** *Mol Cell* 2002, **10**:1247-1253.
- Beale RC, Petersen-Mahrt SK, Watt IN, Harris RS, Rada C, Neuberger MS: **Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra *in vivo*.** *J Mol Biol* 2004, **337**:585-596.
- Liddament MT, Brown WL, Schumacher AJ, Harris RS: **APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 *in vivo*.** *Curr Biol* 2004, **14**:1385-1391.
- Langlois MA, Beale RC, Conticello SG, Neuberger MS: **Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides**

- insight into their DNA target site specificities. *Nucleic Acids Res* 2005, **33**:1913-1923.
27. Lau PP, Zhu HJ, Baldini A, Charnsangavej C, Chan L: **Dimeric structure of a human apolipoprotein B mRNA editing protein and cloning and chromosomal localization of its gene.** *Proc Natl Acad Sci USA* 1994, **91**:8522-8526.
 28. Chiu YL, Soros VB, Kreisberg JF, Stopak K, Yonemoto W, Greene WC: **Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells.** *Nature* 2005, **435**:108-114.
 29. Wedekind JE, Gillilan R, Janda A, Krucinska J, Salter JD, Bennett RP, Raina J, Smith HC: **Nanostructures of APOBEC3G support a hierarchical assembly model of high molecular mass ribonucleoprotein particles from dimeric subunits.** *J Biol Chem* 2006, **281**:38122-38126.
 30. Brar SS, Sacho EJ, Tessmer I, Croteau DL, Erie DA, Diaz M: **Activation-induced deaminase, AID, is catalytically active as a monomer on single-stranded DNA.** *DNA Repair (Amst)* 2008, **7**:77-87.
 31. Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T: **Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme.** *Cell* 2000, **102**:553-563.
 32. Arakawa H, Hauschild J, Buerstedde JM: **Requirement of the activation-induced deaminase (AID) gene for immunoglobulin gene conversion.** *Science* 2002, **295**:1301-1306.
 33. Harris RS, Sale JE, Petersen-Mahrt SK, Neuberger MS: **AID is essential for immunoglobulin V gene conversion in a cultured B cell line.** *Curr Biol* 2002, **12**:435-438.
 34. Revy P, Muto T, Levy Y, Geissmann F, Plebani A, Sanal O, Catalan N, Forveille M, Dufourcq-Labeouze R, Gennery A, Tezcan I, Ersoy F, Kayserli H, Ugazio AG, Brousse N, Muramatsu M, Notarangelo LD, Kinoshita K, Honjo T, Fischer A, Durandy A: **Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2).** *Cell* 2000, **102**:565-575.
 35. Petersen-Mahrt SK, Harris RS, Neuberger MS: **AID mutates *E. coli* suggesting a DNA deamination mechanism for antibody diversification.** *Nature* 2002, **418**:99-103.
 36. Di Noia J, Neuberger MS: **Altering the pathway of immunoglobulin hypermutation by inhibiting uracil-DNA glycosylase.** *Nature* 2002, **419**:43-48.
 37. Imai K, Slupphaug G, Lee WI, Revy P, Nonoyama S, Catalan N, Yel L, Forveille M, Kavli B, Krokan HE, Ochs HD, Fischer A, Durandy A: **Human uracil-DNA glycosylase deficiency associated with profoundly impaired immunoglobulin class-switch recombination.** *Nat Immunol* 2003, **4**:1023-1028.
 38. Bransteitter R, Pham P, Scharff MD, Goodman MF: **Activation-induced cytidine deaminase deaminates deoxycytidine on single-stranded DNA but requires the action of RNase.** *Proc Natl Acad Sci USA* 2003, **100**:4102-4107.
 39. Pham P, Bransteitter R, Petruska J, Goodman MF: **Processive AID-catalysed cytosine deamination on single-stranded DNA simulates somatic hypermutation.** *Nature* 2003, **424**:103-107.
 40. Yang SY, Schatz DG: **Targeting of AID-mediated sequence diversification by cis-acting determinants.** *Adv Immunol* 2007, **94**:109-125.
 41. Di Noia JM, Neuberger MS: **Molecular mechanisms of antibody somatic hypermutation.** *Annu Rev Biochem* 2007, **76**:1-22.
 42. Brar SS, Watson M, Diaz M: **Activation-induced cytosine deaminase (AID) is actively exported out of the nucleus but retained by the induction of DNA breaks.** *J Biol Chem* 2004, **279**:26395-26401.
 43. McBride KM, Barreto V, Ramiro AR, Stavropoulos P, Nussenzweig MC: **Somatic hypermutation is limited by CRM1-dependent nuclear export of activation-induced deaminase.** *J Exp Med* 2004, **199**:1235-1244.
 44. Ito S, Nagaoka H, Shinkura R, Begum N, Muramatsu M, Nakata M, Honjo T: **Activation-induced cytidine deaminase shuttles between nucleus and cytoplasm like apolipoprotein B mRNA editing catalytic polypeptide I.** *Proc Natl Acad Sci USA* 2004, **101**:1975-1980.
 45. Shinkura R, Ito S, Begum NA, Nagaoka H, Muramatsu M, Kinoshita K, Sakakibara Y, Hijikata H, Honjo T: **Separate domains of AID are required for somatic hypermutation and class-switch recombination.** *Nat Immunol* 2004, **5**:707-712.
 46. Lau PP, Xiong WJ, Zhu HJ, Chen SH, Chan L: **Apolipoprotein B mRNA editing is an intranuclear event that occurs posttranscriptionally coincident with splicing and polyadenylation.** *J Biol Chem* 1991, **266**:20550-20554.
 47. Yang Y, Smith HC: **Multiple protein domains determine the cell type-specific nuclear distribution of the catalytic subunit required for apolipoprotein B mRNA editing.** *Proc Natl Acad Sci USA* 1997, **94**:13075-13080.
 48. Chester A, Somasekaram A, Tzimina M, Jarmuz A, Gisbourne J, O'Keefe R, Scott J, Navaratnam N: **The apolipoprotein B mRNA editing complex performs a multifunctional cycle and suppresses nonsense-mediated decay.** *EMBO J* 2003, **22**:3971-3982.
 49. Mehta A, Kinter MT, Sherman NE, Driscoll DM: **Molecular cloning of apobec-1 complementation factor, a novel RNA-binding protein involved in the editing of apolipoprotein B mRNA.** *Mol Cell Biol* 2000, **20**:1846-1854.
 50. Morrison JR, Pászty C, Stevens ME, Hughes SD, Forte T, Scott J, Rubin EM: **Apolipoprotein B RNA editing enzyme-deficient mice are viable despite alterations in lipoprotein metabolism.** *Proc Natl Acad Sci USA* 1996, **93**:7154-7159.
 51. Blanc V, Henderson JO, Newberry EP, Kennedy S, Luo J, Davidson NO: **Targeted deletion of the murine apobec-1 complementation factor (acf) gene results in embryonic lethality.** *Mol Cell Biol* 2005, **25**:7260-7269.
 52. Chester A, Scott J, Anant S, Navaratnam N: **RNA editing: cytidine to uridine conversion in apolipoprotein B mRNA.** *Biochim Biophys Acta* 2000, **1494**:1-13.
 53. Sowden M, Hamm JK, Smith HC: **Overexpression of APOBEC-1 results in mooring sequence-dependent promiscuous RNA editing.** *J Biol Chem* 1996, **271**:3011-3017.
 54. Bishop KN, Holmes RK, Sheehy AM, Malim MH: **APOBEC-mediated editing of viral RNA.** *Science* 2004, **305**:645.
 55. Petersen-Mahrt SK, Neuberger MS: **In vitro deamination of cytosine to uracil in single-stranded DNA by apolipoprotein B editing complex catalytic subunit I (APOBEC1).** *J Biol Chem* 2003, **278**:19583-19586.
 56. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, Neuberger MS, Malim MH: **DNA deamination mediates innate immunity to retroviral infection.** *Cell* 2003, **113**:803-809.
 57. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D: **Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.** *Nature* 2003, **424**:99-103.
 58. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, Gao L: **The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA.** *Nature* 2003, **424**:94-98.
 59. Mariani R, Chen D, Schröfelbauer B, Navarro F, König R, Bollman B, Münk C, Nymark-McMahon H, Landau NR: **Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.** *Cell* 2003, **114**:21-31.
 60. Lecossier D, Bouchonnet F, Clavel F, Hance AJ: **Hypermutation of HIV-1 DNA in the absence of the Vif protein.** *Science* 2003, **300**:1112.
 61. Conticello SG, Harris RS, Neuberger MS: **The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G.** *Curr Biol* 2003, **13**:2009-2013.
 62. Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, Yu XF: **Induction of APOBEC3 ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex.** *Science* 2003, **302**:1056-1060.
 63. Schröfelbauer B, Chen D, Landau NR: **A single amino acid of APOBEC3G controls its species-specific interaction with viron infectivity factor (Vif).** *Proc Natl Acad Sci USA* 2004, **101**:3927-3932.
 64. Zheng YH, Irwin D, Kurosu T, Tokunaga K, Sata T, Peterlin BM: **Human APOBEC3F is another host factor that blocks human immunodeficiency virus type I replication.** *J Virol* 2004, **78**:6073-6076.
 65. Suspène R, Rusniok C, Vartanian JP, Wain-Hobson S: **Twin gradients in APOBEC3 edited HIV-1 DNA reflect the dynamics of lentiviral replication.** *Nucleic Acids Res* 2006, **34**:4677-4684.
 66. Soros VB, Yonemoto W, Greene WC: **Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H.** *PLoS Pathog* 2007, **3**:e15.
 67. Khan MA, Kao S, Miyagi E, Takeuchi H, Goila-Gaur R, Opi S, Gipson CL, Parslow TG, Ly H, Strebel K: **Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type I nucleoprotein complexes.** *J Virol* 2005, **79**:5870-5874.
 68. Luo K, Liu B, Xiao Z, Yu Y, Yu X, Gorelick R, Yu XF: **Amino-terminal region of the human immunodeficiency virus type I nucleocapsid is required for human APOBEC3G packaging.** *J Virol* 2004, **78**:11841-11852.
 69. Schäfer A, Bogerd HP, Cullen BR: **Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor.** *Virology* 2004, **328**:163-168.
 70. Svarovskaia ES, Xu H, Mbisa JL, Barr R, Gorelick RJ, Ono A, Freed EO, Hu WS, Pathak VK: **Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs.** *J Biol Chem* 2004, **279**:35822-35828.

71. Khan MA, Goila-Gaur R, Opi S, Miyagi E, Takeuchi H, Kao S, Strebler K: **Analysis of the contribution of cellular and viral RNA to the packaging of APOBEC3G into HIV-1 virions.** *Retrovirology* 2007, **4**:48.
72. Wang T, Tian C, Zhang W, Sarkis PT, Yu XF: **Interaction with 7SL RNA but not with HIV-1 genomic RNA or P bodies is required for APOBEC3F virion packaging.** *J Mol Biol* 2008, **375**:1098-1112.
73. Cen S, Guo F, Niu M, Saadatmand J, Deflassieux J, Kleiman L: **The interaction between HIV-1 Gag and APOBEC3G.** *J Biol Chem* 2004, **279**:33177-33184.
74. Wichroski MJ, Robb GB, Rana TM: **Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodies.** *PLoS Pathog* 2006, **2**:e41.
75. Huang J, Liang Z, Yang B, Tian H, Ma J, Zhang H: **Derepression of microRNA-mediated protein translation inhibition by apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G (APOBEC3G) and its family members.** *J Biol Chem* 2007, **282**:33632-33640.
76. Rosenberg BR, Papavasiliou FN: **Beyond SHM and CSR: AID and related cytidine deaminases in the host response to viral infection.** *Adv Immunol* 2007, **94**:215-244.
77. Mikl MC, Watt IN, Lu M, Reik W, Davies SL, Neuberger MS, Rada C: **Mice deficient in APOBEC2 and APOBEC3.** *Mol Cell Biol* 2005, **25**:7270-7277.
78. Kusakabe R, Kuratani S: **Evolution and developmental patterning of the vertebrate skeletal muscles: perspectives from the lamprey.** *Dev Dyn* 2005, **234**:824-834.
79. Oota S, Saitou N: **Phylogenetic relationship of muscle tissues deduced from superimposition of gene trees.** *Mol Biol Evol* 1999, **16**:856-867.
80. Holmes RK, Malim MH, Bishop KN: **APOBEC-mediated viral restriction: not simply editing.** *Trends Biochem Sci* 2007, **32**:118-128.
81. Shindo K, Takaori-Kondo A, Kobayashi M, Abudu A, Fukunaga K, Uchiyama T: **The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity.** *J Biol Chem* 2003, **278**:44412-44416.
82. Miyagi E, Opi S, Takeuchi H, Khan M, Goila-Gaur R, Kao S, Strebler K: **Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1.** *J Virol* 2007, **81**:13346-13353.
83. Schumacher AJ, Haché G, Macduff DA, Brown WL, Harris RS: **The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction.** *J Virol* 2008, **82**:2652-2660.
84. Esnault C, Heidmann O, Delebecque F, Dewannieux M, Ribet D, Hance AJ, Heidmann T, Schwartz O: **APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses.** *Nature* 2005, **433**:430-433.
85. Jern P, Stoye JP, Coffin JM: **Role of APOBEC3 in genetic diversity among endogenous murine leukemia viruses.** *PLoS Genet* 2007, **3**:e183.
86. Kaiser SM, Emerman M: **Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G.** *J Virol* 2006, **80**:875-882.
87. Langlois MA, Neuberger MS: **Human APOBEC3G can restrict retroviral infection in avian cells and acts independently of both UNG and SMUG1.** *J Virol* 2008, doi:10.1128/JVI.02469-07.
88. Guo F, Cen S, Niu M, Saadatmand J, Kleiman L: **The inhibition of tRNALys3-primed reverse transcription by human APOBEC3G during HIV-1 replication.** *J Virol* 2006, **80**:11710-11722.
89. Macduff DA, Neuberger MS, Harris RS: **MDM2 can interact with the C-terminus of AID but it is inessential for antibody diversification in DT40 B cells.** *Mol Immunol* 2005, **43**:1099-1108.
90. Chaudhuri J, Khuong C, Alt FW: **Replication protein A interacts with AID to promote deamination of somatic hypermutation targets.** *Nature* 2004, **430**:992-998.
91. Basu U, Chaudhuri J, Alpert C, Dutt S, Ranganath S, Li G, Schrum JP, Manis JP, Alt FW: **The AID antibody diversification enzyme is regulated by protein kinase A phosphorylation.** *Nature* 2005, **438**:508-511.
92. McBride KM, Gazumyan A, Woo EM, Barreto VM, Robbiani DF, Chait BT, Nussenzweig MC: **Regulation of hypermutation by activation-induced cytidine deaminase phosphorylation.** *Proc Natl Acad Sci USA* 2006, **103**:8798-8803.
93. Pasqualucci L, Kitauro Y, Gu H, Dalla-Favera R: **PKA-mediated phosphorylation regulates the function of activation-induced deaminase (AID) in B cells.** *Proc Natl Acad Sci USA* 2006, **103**:395-400.
94. Shen HM, Bozek G, Pinkert CA, McBride K, Wang L, Kenter A, Storb U: **Expression of AID transgene is regulated in activated B cells but not in resting B cells and kidney.** *Mol Immunol* 2007, **45**:1883-1892.
95. Chatterji M, Unniraman S, McBride KM, Schatz DG: **Role of activation-induced deaminase protein kinase A phosphorylation sites in Ig gene conversion and somatic hypermutation.** *J Immunol* 2007, **179**:5274-5280.
96. Okazaki IM, Hiai H, Kakazu N, Yamada S, Muramatsu M, Kinoshita K, Honjo T: **Constitutive expression of AID leads to tumorigenesis.** *J Exp Med* 2003, **197**:1173-1181.
97. Yamanaka S, Balestra ME, Ferrell LD, Fan J, Arnold KS, Taylor S, Taylor JM, Innerarity TL: **Apolipoprotein B mRNA-editing protein induces hepatocellular carcinoma and dysplasia in transgenic animals.** *Proc Natl Acad Sci USA* 1995, **92**:8483-8487.
98. Okazaki IM, Kotani A, Honjo T: **Role of AID in tumorigenesis.** *Adv Immunol* 2007, **94**:245-273.
99. Ramiro AR, Jankovic M, Eisenreich T, Difilippantonio S, Chen-Kiang S, Muramatsu M, Honjo T, Nussenzweig A, Nussenzweig MC: **AID is required for c-myc/IgH chromosome translocations in vivo.** *Cell* 2004, **118**:431-438.
100. Franco S, Gostissa M, Zha S, Lombard DB, Murphy MM, Zarrin AA, Yan C, Tepsuporn S, Morales JC, Adams MM, Lou Z, Bassing CH, Manis JP, Chen J, Carpenter PB, Alt FW: **H2AX prevents DNA breaks from progressing to chromosome breaks and translocations.** *Mol Cell* 2006, **21**:201-214.
101. Ramiro AR, Jankovic M, Callen E, Difilippantonio S, Chen HT, McBride KM, Eisenreich TR, Chen J, Dickins RA, Lowe SW, Nussenzweig A, Nussenzweig MC: **Role of genomic instability and p53 in AID-induced c-myc-IgH translocations.** *Nature* 2006, **440**:105-109.
102. Pasqualucci L, Bhagat G, Jankovic M, Compagno M, Smith P, Muramatsu M, Honjo T, Morse HC, Nussenzweig MC, Dalla-Favera R: **AID is required for germinal center-derived lymphomagenesis.** *Nat Genet* 2008, **40**:108-112.
103. Matsumoto Y, Marusawa H, Kinoshita K, Endo Y, Kou T, Morisawa T, Azuma T, Okazaki IM, Honjo T, Chiba T: **Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium.** *Nat Med* 2007, **13**:470-476.
104. Madsen P, Anant S, Rasmussen HH, Gromov P, Vorum H, Dumanski JP, Tommerup N, Collins JE, Wright CL, Dunham I, MacGinnitie AJ, Davidson NO, Celis JE: **Psoriasis upregulated phorbolin-1 shares structural but not functional similarity to the mRNA-editing protein apobec-1.** *J Invest Dermatol* 1999, **113**:162-169.
105. Machida K, Cheng KT, Sung VM, Shimodaira S, Lindsay KL, Levine AM, Lai MY, Lai MM: **Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenes.** *Proc Natl Acad Sci USA* 2004, **101**:4262-4267.
106. Rose KM, Marin M, Kozak SL, Kabat D: **Transcriptional regulation of APOBEC3G, a cytidine deaminase that hypermutates human immunodeficiency virus.** *J Biol Chem* 2004, **279**:41744-41749.
107. Wedekind JE, Dance GS, Sowden MP, Smith HC: **Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business.** *Trends Genet* 2003, **19**:207-216.
108. Hou HF, Liang YH, Li LF, Su XD, Dong YH: **Crystal structures of Streptococcus mutans 2'-deoxycytidylate deaminase and its complex with substrate analog and allosteric regulator dCTP x Mg²⁺.** *J Mol Biol* 2008, **377**:220-231.
109. **Ensembl Genome Browser** [http://www.ensembl.org]
110. **WebLogo** [http://weblogo.berkeley.edu]